Colchicine in Patients with Acute Ischaemic Stroke or Transient Ischaemic Attack (CHANCE-3)

Key Findings

The study aimed to determine the effectiveness and safety of colchicine in reducing the risk of subsequent stroke after high risk non-cardioembolic ischaemic stroke or transient ischaemic attack within the first three months of symptom onset.

Study Design

This was a multicentre, double blind, randomised, placebo controlled trial conducted in 244 hospitals in China between 11 August 2022 and 13 April 2023.

Participants

A total of 8343 patients aged 40 years or older with a minor-to-moderate ischaemic stroke or transient ischaemic attack and a high sensitivity C-reactive protein ≥2 mg/L were enrolled.

Treatment

Patients were randomly assigned to receive either colchicine or placebo for 90 days, starting within 24 hours of symptom onset.

Outcomes

The primary efficacy outcome was any new stroke within 90 days after randomisation. The primary safety outcome was any serious adverse event during the treatment period.

Results

The study found that colchicine did not significantly reduce the risk of subsequent stroke within 90 days compared to placebo among patients with acute non-cardioembolic minor-to-moderate ischaemic stroke or transient ischaemic attack and a high sensitivity C-reactive protein ≥2 mg/L.

Implications

These findings suggest limited benefit of low-dose colchicine in this patient population.

Clinical Trial Registration

ClinicalTrials.gov, NCT05439356

DocSym: Advancing Clinical Practice

DocSym, our AI-driven platform, consolidates ICD-11 standards, clinical protocols, and research into a single, easily accessible knowledge base for clinicians, helping to extend the benefits of clinical trials into everyday medical practice.

Streamlining Healthcare Operations

Our mobile apps support scheduling, monitoring treatments, and telemedicine, making it easier to manage patient care and expand services digitally in today’s healthcare environment.